Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Mainz Biomed NV (MYNZ) had Revenue of $0.89M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$0.89M
Net Income	$-21.65M
Cost of Goods Sold	$0.32M
Gross Profit	$0.57M
Operating Expenses	$19.59M
Operating Income	$-18.70M
Non-Operating Income/Expense	$-2.96M
Pre-Tax Income	$-21.65M
Normalized Pre-Tax Income	$-21.68M
Income after Taxes	$-21.65M
Income from Continuous Operations	$-21.65M
Consolidated Net Income/Loss	$-21.65M
Normalized Income after Taxes	$-21.68M
EBIT	$-18.70M
EBITDA	$-17.68M
Weighted-Average Shares Outstanding (Basic)	0.97M
Weighted-Average Shares Outstanding (Diluted)	0.97M
Earnings per Share (EPS) (Basic)	$-22.36
Earnings per Share (EPS) (Diluted)	$-22.36
Balance Sheet Financials
Current Assets	$7.84M
Property, Plant, and Equipment	$1.37M
Long-Term Assets	$5.39M
Total Assets	$13.24M
Current Liabilities	$5.95M
Long-Term Debt	$0.87M
Long-Term Liabilities	$1.24M
Total Liabilities	$7.19M
Common Equity	$6.05M
Tangible Shareholders Equity	$3.03M
Shareholders Equity	$6.05M
Common Shares Outstanding	2.32M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-17.09M
Cash Flow from Investing Activities	$-0.20M
Cash Flow from Financial Activities	$16.60M
Beginning Cash	$7.07M
End Cash	$6.24M
Increase/Decrease in Cash	$-0.84M
Stock-Based Compensation	$1.14M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.32
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.13
Debt to Equity Ratio	0.37
Gross Margin	64.31%
Operating Margin	-2091.23%
EBIT Margin	-2091.23%
EBITDA Margin	-1977.47%
Pre-Tax Profit Margin	-2421.80%
Profit Margin	-2421.80%
Free Cash Flow	$-17.17M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	0.86
Receiveable Turnover	17.59
Days Sales in Receivables	20.75
Return on Equity	-358.07%
Return on Tangible Equity	-714.76%
Return on Assets	-163.55%
Return on Investments	-313.21%
Book Value Per Share	$2.61
Free Cash Flow per Share	$-17.73
Operating Cash Flow per Share	$-17.65

Data from Zacks Investment Research, Inc.